Table 3.

Inhibition parameters of isobavachin against several CYP and UGT isozymes (Mean ± SD). All experiments were performed in triplicate

Isozymes	Substrate	IC50 (μM)	Inhibition type	Ki (μM)	α	R 2	AIC	SC	Selection
CYP2B6	Bupropion	5.00 ± 0.48	Competitive	0.35 ± 0.11	–	0.9111	14.65	17.64
			Non-competitive	1.93 ± 0.18	–	0.9671	−5.19	−2.21	√
			Mixed-type	1.46 ± 0.62	1.49 ± 0.92	0.9678	−3.64	0.34
CYP2C9	Tolbutamide	0.04 ± 0.005	Competitive	0.11 ± 0.02	–	0.9623	−136.47	−133.48
			Non-competitive	0.22 ± 0.02	–	0.9793	−148.48	−145.49	√
			Mixed-type	0.27 ± 0.10	0.70 ± 0.49	0.9797	−146.85	−142.87
CYP2C19	Mephenytoin	0.27 ± 0.07	Competitive	1.55 ± 0.25	–	0.9724	−113.19	−110.20	√
			Non-competitive	3.34 ± 0.49	–	0.9625	−107.08	−104.10
			Mixed-type	1.55 ± 0.53	>>1	0.9724	−111.19	−107.21
UGT1A1	Estradiol	1.53 ± 0.39	Competitive	3.05 ± 0.41	–	0.9857	225.43	228.42	√
			Non-competitive	3.32 ± 0.38	–	0.9854	225.80	228.79
			Mixed-type	3.10 ± 1.23	8.01 ± 2.56	0.9856	227.49	231.47
UGT1A9	propofol	1.21 ± 0.30	Competitive	0.20 ± 0.03	–	0.9676	121.43	124.42
			Non-competitive	0.44 ± 0.04	–	0.9807	111.03	114.02	√
			Mixed-type	0.43 ± 0.14	1.05 ± 0.70	0.9807	113.02	117.01
UGT2B7	zidovudine	0.09 ± 0.01	Competitive	0.02 ± 0.00	–	0.9511	232.70	235.68
			Non-competitive	0.05 ± 0.01	–	0.9766	217.93	220.91	√
			Mixed-type	0.04 ± 0.01	1.80 ± 0.93	0.9781	218.55	222.54